WP-EAGSAKELEGDPVAG
Whitmania pigra-derived 15-residue anti-atherosclerosis peptide — Hu 2020 demonstrates inhibition of macrophage migration via JNK + p38 MAPK pathways.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Whitmania pigra-derived 15-residue anti-atherosclerosis peptide — Hu 2020 demonstrates inhibition of macrophage migration via JNK + p38 MAPK pathways.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
Clinical translation limit
WP-EAGSAKELEGDPVAG's in vitro macrophage anti-migration activity does NOT establish clinical anti-atherosclerosis efficacy. No FDA-approved derivative exists; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.
Molecular Profile
- Category
- Anti-inflammatory
- Evidence tier
- Preclinical
- Molecular weight
- 1,480 Da
- Source species
- Whitmania pigra
- Discovered
- 2020 · Hu B et al.
Biological Targets
- → macrophage migration
- → JNK pathway
- → p38 MAPK pathway
- → MEKK4 / ASK2 signaling
Key Citations
- Hu B et al. (2020), J Ethnopharmacol · PMID 32119950
External Resources
Related Anti-inflammatory Compounds
Leech C1 Inhibitor (LCi)
Complement system modulator targeting C1q activation — immunological homeostasis.
Leech Eicosanoid Modulator
Modulates prostaglandin and leukotriene cascades — anti-inflammatory pathway.
Leech Phospholipase A2 Inhibitor
Putative PLA2 inhibitor identified in leech salivary transcriptome — candidate eicosanoid-cascade modulator.
Haemadipsa yanyuanensis Progranulin (Hy-PGRN)
Putative progranulin gene with 122 cysteine residues and nine tandem repeats — distinctive structural organization (Lin 2025 chromosome-level genome).